Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5CNS 5Other hematologic neoplasm 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myelodysplastic Syndromes 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Leukemia, Myelomonocytic, Chronic 4Anemia, Refractory, with Excess of Blasts 4Myeloproliferative Disorders 3Multiple Myeloma 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3beta-Thalassemia 2Neoplasm, Residual 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Leukemia 2Hematologic Neoplasms 2Anemia, Aplastic 2Thrombocytopenia 1Thrombocythemia, Essential 1Thalassemia 1Primary Myelofibrosis 1Polycythemia Vera 1Neurofibromatosis 1 1Neoplasms, Plasma Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

sodium thiosulfate 1pegfilgrastim 1etoposide phosphate 1Temozolomide 1Rituximab 1Radiotherapy 1Granulocyte Colony-Stimulating Factor 1Fluorescent Antibody Technique 1Filgrastim 1Etoposide 1Cytarabine 1Cyclophosphamide 1Comparative Genomic Hybridization 1Carboplatin 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Rituximab × Classical hematology × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡